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Background: The benefit of drug-eluding stents (DES) in reducing target vessel revascularization (TVR) is greatest in patients at high risk of 
restenosis with bare metal stents (BMS). Lowering the risk of TVR with DES must be weighed against the potential increased risks of stent thrombosis 
and of bleeding from longer dual anti-platelet therapy with DES use. We report the relationship between DES use and patient-specific risk of TVR.
methods: We used 2009-2011 data from our northern New England registry of consecutive PCIs. We excluded patients with prior CABG, who did 
not receive a stent, received both stent types, received a stent <2.25 mm or >4.00 mm or whose propensity score made it very unlikely or very likely 
to receive a DES. The risk of TVR was predicted using patient characteristics, indication, and coronary anatomy. We categorized the risk of TVR as 
L(ow) <10%, M(oderate) = 10-20% and H(igh) > 20%.
results: Among 4,847 patients, 24.1% received a BMS and 67.3% received a DES. The risk of TVR among these patient was L = 20%, M = 60%, 
H = 20%. The use of DES did not vary by the underlying risk of TVR (Figure; p=0.09). While the overall use of DES varied across sites from 62.8% to 
83.4%, at no site did the use of DES vary significantly by the underlying risk of TVR (p=0.071)
conclusion: In our regional experience the use of DES is independent of the risk of TVR. To the extent that we can provide physicians with real time 
estimates of patient-specific risks of TVR there is an opportunity to improve the safety and decrease the costs of care.
